A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
We describe a recently developed immunoassay platform based on the principles of cell-free synthetic biology and the dot-blot technique for customizable detection of antibody response in human and animal sera.
The string of global pathogenic outbreaks over the past two decades has highlighted the importance of serosurveillance strategies. Immunoassay platforms that serve to detect disease-specific antibodies in patients' sera are at the core of serosurveillance. Common examples include enzyme-linked immunosorbent assays and lateral flow assays; however, while these are gold standard methods, they require pathogen-specific consumables and specialized equipment, which limits their use outside of well-resourced laboratories.
We have recently developed a novel immunoassay platform called Cell-Free Dot-Blot (CFDB) and validated it using human and animal sera against SARS-CoV-2. Unlike conventional immunoassays, CFDB patient serum samples are immobilized to a solid phase (nitrocellulose membrane), while the target antigen is suspended in the mobile phase of the assay. To improve access to serosurveillance capabilities, CFDB antigens are produced on demand and with low-burden infrastructure using in vitro protein expression. Here, the antigen is fused with a peptide tag that can be detected using a single universal reporter protein for any CFDB assay. The result is that the CFDB does not require access to a multi-well plate reader or purified commercial molecular assay components. With these design considerations, CFDB addresses the shortcomings of existing immunoassay platforms by providing accessibility to non-centralized laboratories, adaptability for emerging pathogens, and affordability for lower-income communities.
In the current article, we will provide a step-by-step protocol to prepare and perform a CFDB immunoassay. Using our recent work on SARS-CoV-2 CFDB as an example, we will cover antigen DNA design for on-demand cell-free production, followed by preparation of the CFDB reporter protein, immobilization of serum samples on the solid phase, and finally, antigen-binding and detection steps of the assay. We anticipate that by following these instructions, researchers will be able to adapt the CFDB assay to detect immune responses in human and animal sera to any given pathogen.
The COVID-19 pandemic revealed the critical need for affordable, scalable diagnostic tools, particularly for low-resource settings1. Conventional immunoassays like enzyme-linked immunosorbent assays (ELISAs) have proven essential for detecting immune responses2,3. However, their high cost, reliance on complex reagents, and dependence on specialized equipment limit their accessibility, especially during global health crises. In response to these challenges, we developed the Cell-Free Dot Blot (CFDB), a low-cost, adaptable immunoassay platform designed for the detection of anti-SARS-CoV-2 antibodies in human and animal sera.
CFDB leverages cell-free synthetic biology for the rapid, on-demand production of viral antigens using linear DNA templates4,5. This eliminates the need for traditional cell-based cloning, expression, and purification processes, significantly speeding up antigen production while reducing costs. The CFDB method simplifies antibody detection by using a dot blot format, where sera are directly spotted onto nitrocellulose membranes. This system obviates the need for expensive multi-well plates and specialized lab equipment, allowing for a simple "dipping" workflow for incubation and wash steps. The platform also utilizes a SpyCatcher-SpyTag system, where a SpyCatcher2-Apex2 peroxidase chimera acts as a universal secondary detection reagent5,6. This is produced using standard Escherichia coli-based expression, which eliminates dependence on costly commercial antibody conjugates. As a result, the CFDB system can perform serological assays with performance comparable to ELISAs at a significantly lower cost-about $3 USD per 96 sample assay compared to over $300 USD for a commercial ELISA kit5.
To demonstrate CFDB's effectiveness, we tested its ability to detect antibodies in precharacterized human and animal sera. Our results closely correlated with ELISA in identifying COVID-19-positive and -negative samples. In addition to human diagnostics, we evaluated CFDB's utility in animal models, testing sera from SARS-CoV-2-infected hamsters and those vaccinated with recombinant Nucleocapsid protein. These tests confirmed CFDB's potential for use in both human and veterinary diagnostics, making it a versatile tool for monitoring immune responses across species. One of the key advantages of CFDB is its flexibility. By simply modifying the DNA template encoding the antigen of interest, the platform can be rapidly adapted to detect antibodies against different pathogens, making it valuable for future pandemic preparedness. Its low cost, simple workflow, and minimal infrastructure requirements make it particularly suitable for decentralized laboratories and low-resource environments, where access to commercial diagnostics is limited.
In this work we will provide step-by-step instructions for preparing and conducting a CFDB assay. First, we cover the design and synthesis of linear DNA templates for cell-free production of antigens, which are the assay's primary detection reagents. We then describe steps for the preparation of the assay's secondary detection reagent SpyCatcher2-Apex2. After that, we provide instructions for the cell-free production and quality-check of antigens themselves. Finally, we describe in detail the process for conducting a CFDB assay on human or animal serum samples.
All hamster experiments were performed at the National Microbiology Laboratory (NML) at the Public Health Agency of Canada, approved by the Canadian Science Centre for Human and Animal Health, and following the Canadian Council on Animal Care guidelines. All human serum/plasma samples were obtained commercially for in-house testing or provided by clinical collaborators to the NML for independent testing at the NML.
1. Design and preparation of antigen linear expression templates (LETs)
Figure 1: Linear expression template for SARS-CoV-2-NP. A schematic representing features of the His-SpyTag-SARS-CoV-2 NP linear DNA template. Key DNA template elements are labeled. The coding sequence for the protein of interest, here the NP, is placed under the transcriptional control of a T7 promoter for efficient expression. At the N-terminus, the NP protein is appended with a SpyTag for specific detection using the SpyCatcher2-Apex2 detection reagent. The x6His-tag and TEV protease sites, although included as part of the general LET design, are dispensable for CFDB purposes. At the termini of the linear DNA template, "upstream" and "downstream" Ter sites, each preceded by respective 50 base pair buffer sequences, are included for Tus-mediated protection against exonucleolytic DNA degradation in the cell-free lysate. Abbreviations: NP = nucleocapsid protein; LET = linear expression template; TEV = tobacco etch virus; CFDB = cell-free dot blot. Please click here to view a larger version of this figure.
2. Purification of the SpyCatcher2-Apex2 reporter protein
3. Cell-free production and quality check of antigens
4. Serum samples
5. Cell-free Dot Blot (CFDB) procedure
Figure 2: CFDB assembly. A schematic of the CFDB master grid and NC membrane assembly setup. The master grid is overlaid on the NC membrane to provide a regular, addressable pattern for spotting and immobilization of serum samples. Abbreviations: CFDB = cell-free dot blot; NC = nitrocellulose. Please click here to view a larger version of this figure.
Figure 3: A schematic representation of the CFDB workflow. In a CFDB assay, a small amount (<0.4 μL) of 10x diluted serum samples is manually dispensed onto a precut nitrocellulose membrane (left panel) in discrete, addressable locations (middle panel). Depositing one serum sample per spot in triplicate spots and immobilizing the protein content, including the sera's total antibody reservoir, on the solid NC substrate (beige spots in the middle panel). In this example, anti-NP antibodies contained in the serum samples can be first bound by the CFDB primary detection reagent SpyTag-NP and finally detected by the CFDB secondary detection reagent SpyCatcher2-Apex2 (right panel-magnified bubble). This figure was taken from Norouzi et al.5. Abbreviations: CFDB = cell-free dot blot; NP = nucleocapsid protein; LET = linear expression template. Please click here to view a larger version of this figure.
PCR amplification of the linear expression template for target antigen
To PCR-amplify the SARS-CoV-2 NP LET, universal Ter forward and reverse primers were used as described in protocol section 1.2 and 1 μL of the product was checked on an agarose gel (Figure 4) before proceeding to the purification of the PCR product.
COVID-19 highlighted the importance of accessible and robust diagnostics for controlling infection outbreaks and optimizing global health strategies. Serological testing that detects protective antibodies proved essential for tracking transmissibility patterns of new variants, identifying hot spots, guiding vaccine development, triaging suspected cases and protecting vulnerable populations14. The pandemic also exposed inequities in testing accessibility, exasperated by backlogs and requirements fo...
M.N. and K.P. are co-inventors of the cell-free dot blot method. A provisional patent application related to this work has been filed (PCT/CA2024/050097, filed January 2024).
S.S. and R.Z. are supported by funding from the Defense Advanced Research Projects Agency (DARPA), Contract No. N66001-23-2-4042. The views, opinions, and/or findings expressed are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. This work was supported by funds to K.P. from the CIHR Foundation grant program (201610FDN-375469), CIHR Canada Research Chair Program (950-231075 and 950-233107), University of Toronto's Medicine by Design Initiative, which receives funding from the Canada First Research Excellence Fund and funds to K.P., from Defense Research and Development Canada's, Canadian Safety and Security Program (contract 39903-200137). Figure 1 and Supplemental Figure S1 were created using SnapGene Viewer.
Name | Company | Catalog Number | Comments |
1 kb DNA ladder | NEB | N3232 | Used as a size marker for agarose gels |
20 Amino acids | Sigma-Aldrich | LAA21-1KT | A component of the cell-free reaction Solution B |
2 mm biopsy punch | Integra Miltex | 33-31-P/25 | For preparation of CFDB master grid |
5-aminolevulinic acid hydrochloride | Sigma-Aldrich | A3785 | Heme precursor for induction of SpyCatcher2-Apex2 |
Agarose powder | BioShop | AGA002 | For electrophoretic analysis of DNA |
Anti-SARS-CoV2-Nucleocapsid antibody | Sinobiological | 40588-T62 | For WB detection of cell-free produced NP antigen |
Bio-Rad ChemiDoc XRS+ | Bio-Rad | N/A | Gel imager instrument |
Centrifugal concentrators | Cytiva | 28-9323-60 | For concentration and buffer exchange of proteins |
Centrifuge | Eppendorf | EP022628257 | For harvesting bacterial culture |
Coenzyme A sodium salt hydrate (CoA) | Sigma-Aldrich | C3144 | A component of the cell-free reaction Solution A |
Color pre-stained protein standard (broad range) | NEB | P7719 | Used as a size marker for SDS-PAGE gels |
Covid-19 serum panel | RayBiotech | CoV-PosSet | Pre-characterised sera for verification and optimisation of CFDB reagents/conditions |
D-(−)-3-Phosphoglyceric acid disodium salt (3-PGA) | Sigma-Aldrich | P8877 | A component of the cell-free reaction Solution B |
Dithiothreitol (DTT) | Sigma-Aldrich | 10197777001 | Component of buffers |
E. coli 5-alpha | NEB | C2987 | for plasmid preparation |
E. coli BL21 | NEB | C2530 | For preparation of cell-free lysates |
E. coli BL21 (DE3) | NEB | C2527 | For expression of SpyCatcher2-Apex2 |
EDTA-free protease inhibitor tablet | Sigma-Aldrich | 11836153001 | A component of E. coli lysis buffer |
Eppendorf New Brunswick Innova 43/43R Incubator Shaker | Eppendorf | EPM1320 | Incubator for growing E. coli cells for protein expression and cell-free lysate preparation |
Folinic acid | Sigma-Aldrich | 47612 | A component of the cell-free reaction Solution A |
Glycerol | Sigma-Aldrich | G9012 | Component of SpyCatcher2-Apex2 storage buffer |
Hemin chloride | Sigma-Aldrich | H9039 | For Heme supplementation of SpyCatcher2-Apex2 |
Hydrogen peroxide 30% | Sigma-Aldrich | H1009 | For making ECL reagent |
Image Lab Software | Bio-Rad | 1709690 | Software for ChemiDoc gel imaging instrument |
Isopropyl-b-D-1-thiogalactopyranoside | Bioshop | IPT001 | For induction of SpyCatcher2-Apex2 expressikon |
Kanamycin Sulfate | Sigma-Aldrich | 60615 | For preparation of SpyCatcher2-Apex2 bacterial culture |
LB agar | BioShop | LBL406 | For E. coli growth |
LB broth | BioShop | LBL407 | For E. coli growth |
luminol | Sigma-Aldrich | A4685 | For making ECL reagent |
Lysozyme | Sigma-Aldrich | L6876 | For lysis of bacterial cells |
Magnesium Acetate | Sigma-Aldrich | M5661 | A component of the cell-free reaction Solution B |
NEBExpress Ni resin | NEB | S1428S | For purification of SpyCatcher2-Apex2 |
Non-fat dry milk | Bioshop | SKI400 | For blocking of WB and CFDB membranes |
Parafilm | Bemis | 2099-1337410 | For ECL-incubation of CFDB blots |
p-coumaric acid | Sigma-Aldrich | C9008 | For making ECL reagent |
pET24b-SpyCatcher2-Apex2 plasmid | Pardee Laboratory | N/A | Used for the expression of SpyCatcher2-Apex2 protein |
Petri dish | Fisherbrand | FB0875712 | Container for WB and CFDB membrane incubation |
Phosphate buffered saline 10% | BioShop | PBS405 | Component of buffers |
Potassium Glutamate | Sigma-Aldrich | G1501 | A component of the cell-free reaction Solution B |
Potassium Oxalate Monohydrate (Oxalic acid) | Sigma-Aldrich | 223425 | A component of the cell-free reaction Solution A |
Precast SDS-PAGE gel | BioRad | 4561036EDU | For electrophoretic analysis of protein |
Q5 high-fidelity DNA polymerase | NEB | M0491 | For PCR amplification of LETs |
QIAquick PCR purification kit | Qiagen | 28106 | For purification of LETs |
Ribonucleotide Solution Set | NEB | N0450S | A component of the cell-free reaction Solution A |
Skim milk powder | BioShop | SKI400 | Used as a blocking agent for western blot and CFDB |
Sodium Chloride | Sigma-Aldrich | S9625 | A component of protein purification buffers |
Sonicator | Qsonica | Q500 | For lysis of bacterial cells |
Spermidine | Sigma-Aldrich | S2626 | A component of the cell-free reaction Solution A |
Syringe filter | Sigma-Aldrich | SLGSR33SS | For sterilisation of buffers and solutions |
Thermocycler | BioRad | T100 | Instrument for incubating PCR reactions |
Transfer RNA (tRNA) | Sigma-Aldrich | R8759 | A component of the cell-free reaction Solution A |
Tris buffered saline | Thermo Scientific | J60764.K2 | Component of WB and CFDB wash buffer |
Trizma base | Sigma-Aldrich | T1503 | For making tris buffer |
Tunair SS-5012 Half-Baffle Shake Flask, 2.5 L | Cole-Parmer | RK-01835-39 | Vessel for growing E. coli cells for protein expression and cell-free lysate preparation |
Tween-20 | BioShop | TWN510 | Component of WB and CFDB wash buffer |
Tweezer | Almedic | 7728-A10-100 | For handling CFDB NC membrane |
UV-Vis spectrophotometer | Thermo Scientific | 13400518 | Used for the measurement of nucleic acid and DNA concentration and bacterial culture OD |
WHO International Reference Panel for anti-SARS-CoV-2 immunoglubulin | NISBC | 20/268 | Pre-characterised sera for verification and optimisation of CFDB reagents/conditions |
β-Nicotinamide adenine dinucleotide hydrate (NAD) | Sigma-Aldrich | 10127965001 | A component of the cell-free reaction Solution A |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved